Lilly gets FDA warning on plant that makes Humalog ingredient

02/24/2010 | Wall Street Journal, The

Eli Lilly and Co. received a warning letter from the FDA citing its lack of "sufficient corrective actions" on manufacturing violations at a Puerto Rican plant that produces the active ingredient in diabetes drug Humalog. A Lilly spokesman said the drugmaker is working to address the concern and that the matter has "no safety and efficacy implications for patients."

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI